me 3221 has been researched along with Brain Vascular Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, M; Hachisu, M; Hui, C; Konno, F; Nagura, J; Yamamoto, M; Yasuda, S | 2 |
2 other study(ies) available for me 3221 and Brain Vascular Disorders
| Article | Year |
|---|---|
ME3221, a surmountable angiotensin AT1-receptor antagonist, prevents hypertensive complications in aged stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Brain; Cerebrovascular Disorders; Enalapril; Heart; Hypertension; Imidazoles; Kidney; Losartan; Male; Myocardium; Rats; Rats, Inbred SHR; Tetrazoles | 1996 |
Effect of chronic treatment with ME3221 on blood pressure and mortality in aged stroke-prone spontaneously hypertensive rats.
Topics: Aging; Angiotensin I; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cerebral Hemorrhage; Cerebrovascular Disorders; Hypertension; Longevity; Male; Organ Size; Rats; Rats, Inbred SHR; Survival Rate; Tetrazoles | 1995 |